Teriflunomide is a once-daily oral immunomodulator approved for treating relapsing forms of MS (RMS) and relapsing-remitting MS, depending on the local label. In the phase 4, real-world Teri-PRO study (NCT01895335), patient-reported outcomes in RMS patients showed significantly improved satisfaction with teriflunomide versus prior disease-modifying therapy (DMT) at Week 48; safety was consistent with prior teriflunomide trials.
To assess changes in treatment satisfaction stratified by age in Teri-PRO patients who switched to teriflunomide 14 mg from prior DMTs.
Patients switching to teriflunomide 14 mg were stratified by age at baseline (≤35 years [n=85]; >35 to ≤45 years [n=167]; >45 to ≤55 years [n=175]; >55 years [n=129]). Assessment: Treatment Satisfaction Questionnaire for Medication (TSQM version 1.4 [4 domains: Global Satisfaction, Effectiveness, Side Effects, and Convenience; scores: 0-100, higher scores indicate improved satisfaction]) at baseline versus Week 48.
Compared with baseline, mean scores in each TSQM domain were significantly increased at Week 48 in patients aged >35 to ≤45 years (least-squares mean change [LS]: Global Satisfaction, 15.0, P<0.0001; Effectiveness, 6.3, P=0.0157; Side Effects, 20.6, P<0.0001; Convenience, 31.6, P<0.0001), >45 to ≤55 years (LS: Global Satisfaction, 15.4, P<0.0001; Effectiveness, 8.3, P<0.0001; Side Effects, 20.4, P<0.0001; Convenience, 31.0, P<0.0001), and >55 years (LS: Global Satisfaction, 11.3, P=0.0001; Effectiveness, 9.3, P=0.0001; Side Effects, 11.7, P<0.0001; Convenience, 29.8, P<0.0001). In patients aged ≤35 years, significantly improved mean TSQM scores at Week 48 versus baseline were observed in the Side Effects (LS: 26.2, P<0.0001) and Convenience (LS: 28.7, P<0.0001) domains. Across age groups, similar improvements in treatment satisfaction were also seen at Week 4 versus baseline, except for the Effectiveness domain in patients aged ≤35 years.
Over 48 weeks across age groups, patients aged >35 years who switched to teriflunomide 14 mg had significant improvements in all 4 TSQM domains versus baseline, and patients aged ≤35 years experienced significant improvements in the Side Effects and Convenience domains. These findings indicate teriflunomide improves treatment satisfaction regardless of age in RMS patients switching from other DMTs, with improvements occurring as early as Week 4 and persisting at Week 48 of treatment.
STUDY SUPPORT: Sanofi.